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Summary
Genome-wide association studies (GWASs) have identified thousands of cancer risk loci revealing 
many risk regions shared across multiple cancers. Characterizing the cross-cancer shared genetic 
basis can increase our understanding of global mechanisms of cancer development. In this study, 
we collected GWAS summary statistics based on up to 375,468 cancer cases and 530,521 controls 
for fourteen types of cancer, including breast (overall, estrogen receptor [ER]-positive, and ER-
negative), colorectal, endometrial, esophageal, glioma, head/neck, lung, melanoma, ovarian, 
pancreatic, prostate, and renal cancer, to characterize the shared genetic basis of cancer risk. We 
identified thirteen pairs of cancers with statistically significant local genetic correlations across 
eight distinct genomic regions. Specifically, the 5p15.33 region, harboring the TERT and 
CLPTM1L genes, showed statistically significant local genetic correlations for multiple cancer 
pairs. We conducted a cross-cancer fine-mapping of the 5p15.33 region based on eight cancers that 
showed genome-wide significant associations in this region (ER-negative breast, colorectal, 
glioma, lung, melanoma, ovarian, pancreatic, and prostate cancer). We used an iterative analysis 
pipeline implementing a subset-based meta-analysis approach based on cancer-specific conditional 
analyses and identified ten independent cross-cancer associations within this region. For each 
signal, we conducted cross-cancer fine-mapping to prioritize the most plausible causal variants. 
Our findings provide a more in-depth understanding of the shared inherited basis across human 
cancers and expand our knowledge of the 5p15.33 region in carcinogenesis.
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Introduction
Cancer is a major global public health problem. More than 19.3 million new cancer cases 
and 10 million cancer deaths were estimated to occur worldwide in 2020.1 In the United 
States, approximately 1.9 million individuals are projected to be newly diagnosed with 
cancer, and more than 600,000 affected individuals are projected to die of cancer in 2021.2 
Inherited genetic variants, along with environmental exposures, contribute substantially to 
the pathogenesis of cancers. Cancers tend to cluster in families, and twin studies have 
reported cancer-specific heritability ranging from 9% (head/neck) to 58% (melanoma).3,4
Genome-wide association studies (GWASs) of specific types of cancer have identified 
genetic loci significantly associated with susceptibility to malignancies. In a recent study of 
18 types of cancer in European ancestry populations,5 the authors identified 17 genome-
wide significant variants that were associated with the risk of at least two cancers with the 
same direction of effect. The 8q24 region has been long recognized as a pleiotropic locus, 
where genetic variants have been associated with the risk of breast, colorectal, endometrial, 
glioma, ovarian, pancreatic, and prostate cancer, among others.6–16 The 5p15.33 region has 
been associated with more than ten types of cancer, with multiple independent risk alleles 
identified.17–24 Various biological mechanisms, including inflammation, epigenetics, gene 
expression, and telomere structure, have been proposed to explain these identified 
pleiotropic associations. For example, the 5p15.33 region harbors the TERT gene, which 
encodes the catalytic subunit of telomerase,25 as well as the CLPTM1L gene, which encodes 
the cleft lip and palate-associated transmembrane-1 like protein.26
In addition, recent efforts have been devoted toward estimating the genetic correlation 
between pairs of cancers. Using the restricted maximum likelihood (REML) approach 
implemented in the GCTA tool,27 one study quantified the pairwise genetic correlation 
among 13 types of cancers in European ancestry populations.28 Four pairs of cancers, 
including bladder-lung, testis-renal, lymphoma-osteosarcoma, and lymphoma-leukemia, 
demonstrated statistically significant shared heritability. We have previously applied linkage 
disequilibrium (LD) score regression29,30 on cancer GWAS summary statistics and observed 
significant genetic correlations between multiple solid tumor pairs, including colorectal-
lung, colorectal-pancreatic, breast-colorectal, breast-lung, breast-ovarian, and lung-head/
neck cancer.31,32 However, these studies only quantified the pairwise genetic correlation on 
a genome-wide scale, ignoring variations in the local genetic correlation across the genome. 
As shared heritability between cancers may not be uniformly distributed across the genome, 
such limitation may lead to missed opportunities to discover specific regions with crucial 
contribution to the oncogenesis of multiple cancers.33
In the present study, we collected European ancestry-derived GWAS summary statistics 
from large-scale meta-analysis results for 14 types of cancer, based on a total number of 
375,468 cancer cases and 530,521 controls. By partitioning the genome into 1,703 blocks 
based on the LD pattern in the 1000 Genomes (1000G) European ancestry populations,34 we 
systematically estimated pairwise local genetic correlations between cancers. After adjusting 
for multiple comparisons, we identified thirteen pairs of cancers with statistically significant 
local genetic correlations across eight distinct genomic regions. Among these, a 1.2 Mb 
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region at 5p15.33, harboring the TERT and CLPTM1L genes, showed significant local 
genetic correlations across six pairs of cancers, including breast (overall and estrogen 
receptor [ER]-negative), colorectal, glioma, lung, melanoma, pancreatic, and prostate cancer. 
We then utilized an iterative analysis pipeline implementing a subset-based meta-analysis 
approach (Association Analysis for SubSETs [ASSET])35 and a conditional analysis tool 
(COndition and JOint analysis tool implemented in the Genome-wide Complex Trait 
Analysis software, COJO-GCTA)36 and identified ten independent cross-cancer signals 
within the 1.2 Mb region. For each independent signal, we conducted multi-cancer fine-
mapping analysis using PAINTOR37 to prioritize the variants with the highest posterior 
probability of being causal. Our study provides novel evidence of shared genetic 
susceptibility across cancer types and contributes crucial information toward understanding 
the common genetic mechanisms of carcinogenesis.
Material and methods
Study sample and genotype quality control
We collected the meta-analysis results from a total of 14 cancer GWASs: breast (overall, ER-
positive, and ER-negative),38 colorectal,39 endometrial,16 esophageal,40 glioma,41 head/
neck,42 lung,43 melanoma,44 ovarian,45 pancreatic,46 prostate,47 and renal cancer.48 Sample 
size for each cancer is listed in Table 1. The GWAS summary statistics for each cancer were 
provided by the corresponding collaborative consortia. Details on study characteristics and 
subjects contributing to each cancer-specific GWAS summary dataset have been described in 
the original cancer-specific publications. All the GWAS results used in this study were based 
on European ancestry populations. Genomic positions were based on Genome Reference 
Consortium GRCh37 (hg19).
Individual cancer GWASs were primarily imputed to the 1000G reference panels.49 Breast, 
ovarian, pancreatic, and prostate cancer used the 1000G phase 3 v.5 reference panel; 
colorectal cancer used the Haplotype Reference Consortium (HRC); head/neck cancer used 
HRC; renal cancer used 1000G phase 1 v.3; metanalysis results for melanoma GWASs were 
based on studies majorly imputed with 1000G phase 1 v.3;44 lung cancer used a mix 
between 1000G phase 1 and hase 3; glioma used a mix between 1000G phase 3, UK10K, 
and HRC; esophageal cancer used 1000G phase 1; and endometrial cancer used a mix 
between 1000G phase 3 v.5 and UK10K. For each dataset, we conducted comprehensive 
quality control to clean and harmonize the GWAS summary statistics across cancers. This 
included: (1) removing duplicate, structural, multi-allelic, and ambiguous variants; (2) 
confirming that strand and alleles at each variant were consistent across cancers; (3) creating 
a common unique marker ID; and (4) removing analytic artifacts (e.g., common variants 
with reported |log odds ratio| > 3). We also removed any variants with imputation quality 
score<0.3 or minor allele frequency (MAF) < 0.01. After manual inspection of the results, 
we conducted additional ad hoc cleaning for individual cancer results to remove any obvious 
technical artifacts.
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Genetic correlations due to sample overlap
We estimated the number of controls overlapping between pairs of cancers, as these would 
induce a correlation in the GWAS summary statistics between cancers. We identified 
participating studies and any publicly available datasets (e.g., Wellcome Trust Case Control 
Consortium) to calculate the maximum number of controls overlapping between any two 
cancers. We also employed the tetrachoric correlation between binary-transformed GWAS 
summary Z scores to determine putative sample overlap.50,51 To avoid induced correlations 
due to a shared polygenic architecture, we removed all cancer-specific variants with 
association p < 0.1. We observed six pairs of cancers that had correlations > 0.05, and these 
all reflected previously known documented relationships where controls were shared 
between groups (Table S1). Pairs with correlations > 0.05 included breast and endometrial 
(0.08), ER-positive breast and endometrial (0.06), breast and ovarian (0.05), esophageal and 
melanoma (0.08), lung and head/neck (0.07), and lung and renal cancer (0.07).
Local genetic correlation estimation
To identify regions in the genome with local genetic correlations between pairs of cancers, 
we used ρHESS52 (Heritability Estimation using Summary Statistics), which first estimates 
the local SNP-heritability for each cancer within each region based on summary statistics53 
and then quantifies the covariance and correlation between pairs of cancers. Based on the 
LD pattern in 1000G European ancestry populations,34 ρHESS partitions the genome into 
1,703 approximatively independent LD blocks. We took sample overlap between pairs of 
cancers into account as described above. Pairwise local genetic correlations were considered 
statistically significant if the p value < 0.05/1,703 = 2.94 × 10−5.
Searching for independent signals shared across cancers
Based on the local genetic correlation results, we identified a 1.2Mb region at 5p15.33 (hg19 
coordinates: 82,252–2,132,442 bp) harboring significant local heritability for multiple 
cancer pairs (see Results). We selected eight types of cancers (ER-negative breast, 
colorectal, glioma, lung, melanoma, ovarian, pancreatic, prostate) that had genome-wide 
significant associations in the region and showed evidence of pairwise genetic correlation (p 
< 0.05) with at least one other cancer having genome-wide significant associations in this 
region, which includes the TERT and CLPTM1L genes. We first performed a conditional 
analysis using COJO-GCTA36 on each individual cancer adjusting for the variant with the 
smallest p value, until no variant had a conditional p < 5 × 10−8. We then performed 
pairwise colocalization analyses using COLOC54 to assess if any cancers shared causal 
variants, after controlling for the independent signals identified in analysis of individual 
cancers. To comprehensively enumerate the independent cross-cancer signals within this 
locus, we then used an agnostic subset-based meta-analysis (ASSET)35 to identify variants 
with the strongest cross-cancer associations in this region (Figure 1). ASSET allows for 
opposite direction of effects across traits when assessing the association between variants 
and multiple traits, as implemented in the “two-sided” option in ASSET. Overlap in controls 
between GWASs was addressed by using the tetrachoric correlation, as described above. To 
determine the number of independent signals within a region, we reran all individual cancer 
GWASs conditioning on the top variant identified by ASSET using COJO-GCTA. The 
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conditional analysis may be subject to the mismatch of LD between the reference panel and 
the population that generated the GWAS results. Consequently, we created a LD reference 
panel for all cancer-specific conditional analyses using European ancestry breast cancer 
controls (n = 40,401),38 which was the largest population with genotype data available. After 
generating updated cancer-specific GWAS summary statistics conditioned on the most 
significant variant (top variant), we reran the two-sided ASSET meta-analysis to identify any 
additional significant cross-cancer signals. We then added the new top variant from the 
ASSET analysis to the list of lead SNPs and reran all cancer GWASs conditioning on all 
lead variants using COJO-GCTA. We iteratively ran cancer-specific analyses conditioning 
on the identified top variants using COJO-GCTA and ran two-sided ASSET on the resulting 
cancer-specific association results. We repeated this procedure until no variant reached 
genome wide significance in the two-sided ASSET meta-analysis. The lead variants that 
resulted from the two-sided ASSET meta-analyses based on the conditional cancer-specific 
results were regarded as candidate variants that independently affect the risk of multiple 
cancers. Using this approach, we identified a total of ten independent signals within the 
5p15.33 region.
Multi-trait fine-mapping
For each of the ten cross-cancer signals in the 5p15.33 region identified by our ASSET-
COJO analysis, we created new cancer-specific GWAS summary statistics adjusting for the 
other nine top variants and estimated variant-specific posterior probabilities of causality 
using PAINTOR v.3.0.37 We varied the set of cancers included in the fine-mapping analyses 
of each of the ten independent cross-cancer signals as we hypothesized that not all cancers 
would share the same causal variant for each independent signal, but, rather, different 
combinations of cancers contributed to each of the ten independent signals. This was also 
supported by the ASSET analyses, where not all cancers contributed to the top signal for 
each of the ten conditional meta-analyses. In particular, ASSET provides the subset of traits 
that contribute to the smallest variant-specific meta-analysis p value. For each variant, two 
subsets are reported, with the first including traits with a positive association and the second 
including traits with a negative association. For each of the ten independent signals, we 
included a specific cancer in the PAINTOR fine-mapping analysis if: (1) it was one of the 
cancers selected by ASSET as a contributing phenotype in the corresponding two-sided 
ASSET analysis of the lead variant, or (2) the lead variant showed genome-wide significant 
association for that cancer in the unadjusted cancer-specific GWAS. For each independent 
signal, only SNPs with data for all relevant cancers were included. We ran PAINTOR under 
the assumption that there was only one causal variant underlying that signal. We used the 
same LD reference panel for the fine-mapping analysis as we did for the conditional 
analysis. In our primary analyses, we performed the fine-mapping with no functional 
annotation implemented. Since regulation of TERT and CLPTM1L expression has been 
linked to open chromatin conformation in previous analyses,55,56 we conducted a secondary 
analysis incorporating tissue-specific open chromatin annotations as functional prior. We 
obtained open chromatin narrow peaks identified from normal tissue or primary cell lines of 
the relevant organs of each signal, based on the ENCODE project.57 By overlapping variants 
with open chromatin peaks, we generated a binary matrix for the region, which was then 
implemented as the functional prior in the fine-mapping analysis.
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Local genetic correlation revealed specific regions in the genome with shared heritability 
across cancers
We first partitioned the genome into 1,703 regions and estimated the pairwise local genetic 
correlation between fourteen types of cancers. After adjusting for multiple comparisons (p 
value < 0.05/1,703 = 2.94 × 10−5), we identified thirteen pairs of cancers with statistically 
significant local genetic correlation across eight distinct genomic regions (Table 2). Among 
these, seven cancer pairs had positive genetic correlation (4q24: colorectal and prostate; 
5p15.33: ER-negative breast and glioma, melanoma and pancreatic; 5q11.2: overall breast 
and colorectal; 8q24: colorectal and prostate; 17q12: endometrial and prostate; 19p13.11: 
ER-negative breast and ovarian), while six others showed negative genetic correlations 
(1q32: ER-negative breast and prostate; 5p15.33: glioma and prostate, colorectal and glioma, 
ER-negative breast and prostate, lung and pancreatic; 10q26.13: ER-positive breast and 
prostate). The local genetic correlation results mirrored previous observations, in that 
genome-wide significant variants for the identified regions have been previously reported for 
the individual cancers. For example, colorectal and prostate cancer showed significant local 
genetic correlation on chromosome 8 (126,410,917–128,659,111 bp), overlapping the 
8q24.21 region, which harbors susceptibility variants for more than ten types of cancers. 
Similarly, a region on chromosome 19 (16,374,416–18,409,862 bp) showed significant local 
genetic correlation between ovarian and ER-negative breast cancer, both of which have 
genome-wide significant susceptibility variants in this region. One region on chromosome 5 
(982,252–2,132,442 bp), harboring the TERT and CLPTM1L genes, showed significant 
local genetic correlation across six pairs of cancers, including ER-negative breast, colorectal, 
glioma, lung, melanoma, pancreatic, and prostate cancer (Figure 2). Interestingly, the 
direction of the genetic correlations varied between cancer pairs. For example, glioma 
showed significant but opposite local genetic correlations with ER-negative breast (rg = 
0.0014, p = 2.40 × 10−5) and colorectal cancer (rg = −0.0015, p = 1.24 × 10−5). Similarly, 
pancreatic cancer had a positive local genetic correlation with melanoma (rg = 0.0034, p = 
4.85 × 10−6) but a negative genetic correlation with lung cancer (rg = −0.0025, p = 1.39 × 
10−57).
Distinct patterns of regional GWAS association p values for the variants at 5p15.33
Based on the local genetic correlation results, the 5p15.33 region may harbor key genetic 
variants related to multiple cancer types. Indeed, multiple susceptibility variants in this 
region have been reported for at least ten cancer types, including ER-negative breast, 
colorectal, glioma, lung, melanoma, ovarian, pancreatic, and prostate cancer. To obtain a 
more complete understanding of the association patterns in this region, we created cancer-
specific regional association plots for 5p15.33 (Figure 3A). We observed three different 
patterns of association. Pattern A, which includes breast (overall, ER-positive, and ER-
negative), colorectal, glioma, ovarian, and prostate cancer, displayed one sharp genome-wide 
significant signal in a narrow region (~30 kb) overlapping the TERT gene (chr5: 1,253,282–
1,295,178 bp). Pattern B, which includes lung, melanoma, and pancreatic cancer, has a 
broader genome-wide significant signal overlapping both the TERT (chr5: 1,253,282–
1,295,178 bp) and CLPTM1L genes (chr5: 1,317,869–1,345,180 bp) (Figure 3B). Pattern C, 
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which includes endometrial, esophageal, head/neck, and renal cancer, did not have a 
genome-wide significant signal in this region (Figure 3C). Interestingly, the distribution of 
variant-specific associations for some cancers was highly similar but in the opposite 
direction (Figure 3D), suggesting that GWAS associations discovered in this region may 
underly tissue-specific regulations across cancers. The association-based classification of 
cancers was highly consistent with our local genetic correlation results. All cancer types 
showing shared significant local genetic correlation in this region were in either pattern A or 
B, and thus we excluded the cancers belonging to pattern C for further analyses. For breast 
cancer, we limited our analysis to ER-negative breast cancer, as it had the strongest 
association at 5p15.33. Along with colorectal, glioma, lung, melanoma, ovarian, pancreatic, 
and prostate cancer, a total number of eight cancer types were used in the fine-mapping 
cross-cancer analyses.
Ten independent signals were identified based on multi-cancer meta-analysis results
Given the important biological function of the TERT and CLPTM1L genes, previous cancer 
fine-mapping efforts in this region, and the appearance of multiple association peaks for 
some of the cancers, it is plausible to assume that multiple variants in this region affect 
cancer risk independently. To test this assumption, we performed a conditional analysis 
using COJO-GCTA for each cancer to enumerate the independent signals at the 5p15.33 
region. Six of the eight cancers of interest, including ER-negative breast, colorectal, glioma, 
lung, pancreatic, and prostate, were identified with two or more independent variants (Table 
S2). A total number of thirteen variants were identified, of which four were shared by two 
cancer types. By using conditional analysis results of each cancer, we then assessed the 
probability of two cancers sharing a single causal variant using a Bayesian-based 
colocalization approach.54 Glioma and melanoma were estimated to be likely sharing a 
causal variant (posterior probability [PP] = 0.519; Table S3), even after controlling for the 
effect of identified signals of individual cancers. These results suggest that multiple 
independent cross-cancer signals may exist in this region.
However, current state-of-the-art statistical fine-mapping tools often struggle to make 
inference of causality under the assumption of multiple causal variants. Further, it is likely 
that not all cancers share all causal variants. To get an estimate of the number of independent 
association signals across cancers in this region, we conducted iterative meta-analyses using 
individual cancer-specific association results from conditional analysis as generated by 
COJO-GCTA (see Material and methods). We adopted the two-sided analysis scheme in 
ASSET to allow for the detection of effects in opposite directions.
The strongest associated variant in the two-sided ASSET meta-analysis was rs10069690 
(chr5: 1,279,790, p = 4.05 × 10−126; Figure 4), which was positively associated with ER-
negative breast cancer and glioma while negatively associated with pancreatic and prostate 
cancer. We adjusted the cancer-specific GWAS results for rs10069690 using COJO-GCTA, 
and then reran the two-sided ASSET meta-analysis with the rs10069690-adjusted cancer-
specific results. We observed the strongest association for rs465498 (chr5: 1,325,803, p = 
1.75 × 10−59), which was positively associated with melanoma and pancreatic cancer and 
negatively associated with lung cancer. We added rs465498 to the set of variants to be 
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conditioned on in the cancer-specific GWASs and iterated this process until no variant 
reached genome-wide significance (p < 5 × 10−8) in two-sided ASSET meta-analysis. In the 
end, we obtained ten conditionally independent significant SNPs (Table 3; Figure S1). The 
pairwise r2 between the ten SNPs ranged between 0.001 and 0.294 as based on 1000G 
European ancestry data,58 which indicated that the pairwise correlations between the 
identified signals were weak (Figure 5).
For each of the ten independent signals, the number of cancer types contributing to the 
association as identified by ASSET ranged from two to eight. Although SNPs rs10069690 
and rs7705526 were both genome-wide significant variants for ovarian cancer (p = 1.74 × 
10−8 and 1.34 × 10−9, respectively), ASSET did not include ovarian cancer as a contributing 
cancer to the meta-analysis results for either of the SNPs. To ensure that we included all 
relevant cancers in the fine-mapping analysis of each independent signal, we extracted the 
original cancer GWAS results for the ten independent SNPs and manually added any cancers 
to the list of contributing cancers if that cancer showed a genome-wide significant 
association with a specific SNP but was not included on the list of traits optimizing the 
ASSET meta-analysis. For each of the ten SNPs, we then applied COJO-GCTA on each 
included cancer GWAS dataset to obtain cancer-specific results conditioned on the other 
nine lead SNPs and used these adjusted summary statistics in the fine-mapping analyses.
Cross-cancer fine-mapping proposes candidate causal variants shared by cancers
To identify candidate causal SNPs within the ten independent signals identified in the 
conditional analyses, we conducted a multi-cancer fine-mapping analysis using PAINTOR 
for each signal. We first performed fine-mapping analyses with no functional annotation data 
implemented. For the ten candidate signals, the size of credible sets comprising a cumulative 
95% PP of causality ranged from one to fifteen variants (Table 4; Figure S2). All SNPs 
identified as lead SNPs in the conditional analysis were included in the 95% PP credible set 
of the corresponding fine-mapping analysis, with six of them having the highest PP in its set 
(rs35033501: PP = 0.875; rs35334674: PP = 0.987; rs192723047, rs10069690, rs7705526, 
rs2853677: PP > 0.999). The fine-mapping analysis based on the signal identified by SNP 
rs35226131 included data on colorectal, glioma, pancreatic, and prostate cancer. Although 
rs35226131 was identified as the SNP with the highest PP of being causal, the PP was 
relatively modest (PP = 0.273) and comparable to nearby SNPs (rs35161420, PP = 0.239; 
rs61748181, PP = 0.228). Fine-mapping analysis of the signals indexed by rs11414507 (ER-
negative breast and prostate cancer) and rs465498 (lung, melanoma, and pancreatic cancer) 
both identified a SNP located ~5 kb away from the original lead SNP, with the highest PPs 
for rs7712562 (PP = 0.367) and rs380286 (PP = 0.462), respectively. Fine-mapping analysis 
of rs3888705 (ER-negative breast, colorectal, ovarian, pancreatic, and prostate cancer) 
identified a credible set consisting of 15 variants with PPs ranging between 0.01 and 0.10, 
with the lead SNP rs3888705 having a PP of 0.092.
To assess the impact of adding a priori information on functional importance, we 
downloaded tissue-specific open chromatin narrow peaks of normal tissues or primary cell 
lines for the relevant organs for each signal from the ENCODE project (Figure 6; Table S4). 
By overlapping the functional annotations with the variants of interest, we repeated the fine-
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mapping analysis for all the candidate signals (Table 4; Figure S2). Seven of the ten 
candidate signals showed consistent 95% PP credible sets as the previous fine-mapping 
analyses without functional annotations. However, fine-mapping analysis of rs35033501 
(ER-negative breast, lung, melanoma, pancreatic, and prostate cancer) prioritized 
rs71595003, residing in an open chromatin peak for breast epithelial tissue, with a PP of 
0.999. In contrast, rs35033501, which had a PP of 0.875 in the analysis without annotations, 
had a PP < 0.001 when information about open chromatin was added. For the fine-mapping 
analyses of rs11414507 (ER-negative breast, prostate), the size of the 95% PP credible set 
shrank from four to two, which included the index SNP rs11414507 (PP = 0.42) as well as 
rs7712562 (PP = 0.58). Both rs11414507 and rs7712562 were located in open chromatin 
peaks in breast epithelial tissue. Similarly, after we implemented the functional annotation 
data, only two SNPs were included in the 95% PP credible set of the signal indexed by 
rs465498 (lung, melanoma, pancreatic), compared to eight SNPs in the analysis without 
functional information. The index SNP rs465498 had a comparable PP (0.437) as rs421629 
(PP = 0.563), and both SNPs were located within open chromatin peaks in lung tissue.
Discussion
In this study, we leveraged GWAS summary statistics from 14 cancer types to estimate local 
genetic correlations and conduct follow-up fine-mapping of shared cancer regions in the 
genome. By partitioning the genome into independent blocks as defined by LD, we 
comprehensively estimated pairwise local genetic correlations between the included cancers. 
We identified 13 cancer pairs with significant local genetic correlation across eight distinct 
genomic regions. Among these, one region on chromosome 5p15.33 harboring the TERT 
and CLPTM1L genes had statistically significant shared heritability for seven cancer types, 
including ER-negative breast, colorectal, glioma, lung, melanoma, pancreatic, and prostate 
cancer. By utilizing an iterative analysis, we identified ten independent cross-cancer SNP 
signals within this locus. We then conducted fine-mapping analyses for each independent 
signal and generated 95% posterior probability credible sets both without and with a priori 
functional information.
Our pairwise local genetic correlation results were highly consistent with the conclusions of 
previous GWASs and cross-cancer analyses. The pleiotropic effect of variants in the 8q24 
region between multiple types of cancer, including colorectal and prostate cancer, has been 
previously demonstrated and replicated in studies across populations of different ancestries.
12,59,60 The 5p15.33 region, containing the TERT and CLPTM1L genes, has also been 
associated with multiple cancers.17–23 Other significant genomic regions identified in our 
study, including 1q32.1 (ER-negative breast and prostate), 4q24 (colorectal and prostate), 
5q11.2 (overall breast and colorectal), 10q26.13 (ER-positive breast and prostate), 17q12 
(endometrial and prostate), and 19p13.11 (ER-negative breast and ovarian), have also been 
identified as pleiotropic loci in previous analyses.61,62 Previous efforts have been devoted to 
identifying pleiotropic variants, by using either a subset-based meta-analysis approach61 or 
categorizing genome-wide significant loci of multiple cancers by LD patterns.62 Our 
analysis complements these, as we aggregated the per-SNP effect within the loci, estimated 
the local heritability of each cancer, and quantified the local genetic correlation between the 
cancer pairs. These “shared heritability hotspots” identified in our analysis may contain 
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genes with strong effect on multiple cancers or harbor multiple risk variants and biological 
mechanisms that can independently affect the risk of different cancers. Our results can thus 
be utilized to prioritize candidate regions for future discoveries of causal variants and 
functional follow-up.
As the 5p15.33 region harboring the TERT and CLPTM1L genes was the only region that 
displayed more than one statistically significant pairwise genetic correlation, we focused our 
continued efforts on this region. The TERT gene encodes the catalytic subunit of telomerase 
reverse transcriptase,25 which is a crucial enzyme for maintaining telomere length. 
Mendelian randomization studies have shown that genetically determined telomere length is 
associated with the risk of multiple cancer types, including glioma, ovarian, lung, and 
melanoma, but is not associated with the risk of other cancers included here, such as breast 
and prostate.63–65 In our study, we observed local negative genetic correlations and opposite 
direction of SNP effects between specific cancer types, which indicate that genetic variation 
in this region is likely to affect cancer risk through multiple distinct biological pathways, of 
which telomere length is only one implicated mechanism. Meanwhile, the CLPTM1L gene 
encodes the cleft lip and palate-associated transmembrane-1 like protein, which has been 
reported to play a role in cell apoptosis and cytokinesis and is overexpressed in lung and 
pancreatic cancer.66–68 Given its important biological function and significant association 
with a broad set of cancers, we assumed that multiple variants in this region may 
independently influence the risk of various types of cancers. By iteratively conducting 
conditional meta-analyses, we identified ten independent signals (seven in the TERT gene, 
one in the CLPTM1L gene, and two between TERT and CLPTM1L). Our study results are 
comparable to a previous study published by Wang et al.,56 which conducted a subset-based 
meta-analysis across six types of cancers (bladder, glioma, lung, pancreatic, prostate, and 
testicular). Several signals identified in our study have either been proposed (rs10069690, 
rs2853677) or are correlated with the independent signals reported in that study (rs7705526 
versus rs7726159, r2 = 0.87; rs465498 versus rs451360, r2 = 0.34). We only included 
cancers with genome-wide significant signals in this region into the subset-based meta-
analysis and conditional analysis. Compared to the study presented by Wang et al.,56 our 
study further included several common cancers (ER-negative breast, colorectal, melanoma, 
and ovarian), while we did not have data on bladder and testicular cancer. With an increased 
number of cancers and larger sample sizes, we were able to refine the cross-cancer signals in 
this important region. In addition, independent signal rs465498 identified in our study was in 
strong correlation with two previously identified susceptible loci at the CLPTM1L gene, 
including pancreatic cancer SNP rs31490 (r2 = 0.96)69 and lung, melanoma, and prostate 
cancer SNP rs401681 (r2 = 0.96).21,70,71 Our findings imply that the association between the 
CLPTM1L gene and various types of cancer can be potentially attributed to one distinct 
signal.
When estimating the local genetic correlation across cancers, we considered subtypes for 
breast (ER-negative and ER-positive) and lung cancer (adenocarcinoma, small cell, and 
squamous cell). Despite the relatively smaller GWAS sample size (21,468 for ER-negative 
breast cancer compared to 122,977 for overall breast cancer), ER-negative breast cancer 
showed stronger associations and higher genetic correlation with other cancers in the 
5p15.33 region, as compared to ER-positive and overall breast cancer. In contrast, the three 
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subtypes of lung cancer had either no genome-wide significant hits at the 5p15.33 region 
(small cell) or had weaker local genetic correlation estimates (adenocarcinoma and 
squamous cell, data not shown) than overall lung cancer. We thus included ER-negative 
breast cancer and overall lung cancer in the subsequent analyses.
Multiple lead SNPs with high posterior probability have been reported to affect telomere 
length. SNP rs7705526 is significantly associated with telomere length in multiple 
populations.72–75 SNP rs2853677 has been associated with relative telomere length in a 
breast cancer case-only cohort in Han Chinese,76 as well as leukocyte telomere length in a 
European ancestry population.75 SNP rs35226131 is perfectly correlated with a 
nonsynonymous variant (rs61748181) in TERT, which results in a protein-level change from 
alanine to threonine and negatively influences telomere length.15,71 SNP rs10069690 has 
been found to significantly interact with recent use of non-steroidal anti-inflammatory drugs 
(NSAIDs) to alter telomere length in a colorectal cancer case-control study.77 SNP 
rs465498, located in the CLPTM1L gene, has been reported to be significantly associated 
with telomere length among Han Chinese.78 We could not find previous data on the role of 
other five lead SNPs identified by our study, and it is thus possible that other unknown 
mechanisms are involved.
Since previously identified cancer risk SNPs at 5p15.33 have been linked to open chromatin 
conformation,55,56 we further included regions of open chromatin for related tissues from 
the ENCODE project as functional prior in our fine-mapping analysis.57 The results for five 
signals (lead SNPs rs192723047, rs10069690, rs7705526, rs2853677, and rs35334674) 
remained unchanged, with each having a credible set containing one single SNP with a 
posterior probability of 1.00. After incorporating open chromatin peaks as a prior, the 95% 
posterior probability credible sets became smaller for three signals (lead SNPs rs35033501, 
rs11414507, and rs465498), as SNPs located in open chromatin peaks obtained a higher 
posterior probability of being causal. For the other two signals (lead SNPs rs35226131 and 
rs3888705), the size of each 95% credible set was relatively large in analyses with and 
without functional annotations. No SNPs in these regions had a predominantly high 
posterior probability, nor did any of them overlap with the open chromatin peaks of any 
related tissue. The fine-mapping results for these two signals should thus be interpreted with 
extra caution.
Our study has several strengths and limitations. We used cancer GWAS summary statistics 
published by each collaborating consortium, which maximized our sample sizes and 
provided large statistical power. This is also the first study to comprehensively quantify the 
local genetic correlation across multiple common cancers. We innovatively adopted the joint 
analysis pipeline of two-sided ASSET meta-analysis and COJO-GCTA. This approach 
enabled us to both validate the proposed pleiotropic loci and explore novel independent 
signals, under the complex genetic architecture in the 5p15.33 region. It is also important to 
recognize some limitations. Although we chose an internal population (breast cancer 
controls) to generate the LD reference panel for the conditional analyses and fine-mapping, 
bias may still inevitably exist as the mismatch of LD between the reference and the 
population of other cancers. The study population was limited to European ancestry 
individuals only, and therefore any conclusions of our research may not be applicable to 
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other ancestries. Including multiple ancestries would also allow for refinement of the fine-
mapping signals, since LD structure varies between populations. Moreover, some of the 
GWASs included in the present study (e.g., breast and ovarian) shared controls. Although we 
accounted for this overlap in the local genetic correlation analysis and the subset-based 
meta-analysis, we were not able to take these into account in the fine-mapping analysis, as 
PAINTOR currently does not adjust for sample overlap. However, we do not believe this will 
have a qualitative impact on our results. Meanwhile, although our analysis included a large 
number of cancer types, other cancers, including bladder and testicular, which have shown 
genome-wide significant signals in the 5p15.33 region,21,79 were not included. Further, we 
could have missed any potentially causal variants that were not included in our analyses for 
various reasons (e.g., poorly imputed or rare variants). Finally, the tissue-specific open 
chromatin peaks used as the functional prior in our fine-mapping analysis were from adult 
tissue. Some of these tissues may not express much of TERT, and thus these annotations 
may not necessarily reflect a cellular context where TERT and the enhancers that promote 
TERT expression are active. Our fine-mapping analysis should thus be interpreted with some 
caution. Since the fine-mapping analysis was solely based on bioinformatic analysis, further 
functional validation using molecular biology experiments is required to fully understand the 
mechanisms at play in this region.
In summary, our study identified genomic regions with significant local genetic correlations 
across 14 types of common cancers. We further enumerated the independent pleiotropic 
signals in the 5p15.33 region and performed a cross-cancer fine-mapping for each signal, 
using up-do-date bioinformatics tools. Results from our study provide novel evidence of the 
shared inherited basis of human cancers and expand our understanding of the role played by 
the TERT-CLPTM1L region in cancer development.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Authors 
Hongjie Chen1, Arunabha Majumdar2,3, Lu Wang4, Siddhartha Kar5, Kevin M. 
Brown6, Helian Feng7, Constance Turman8, Joe Dennis9, Douglas Easton9, Kyriaki 
Michailidou10,11, Jacques Simard12, Breast Cancer Association Consortium 
(BCAC), Timothy Bishop13, Iona C. Cheng14, Jeroen R. Huyghe15, Stephanie L. 
Schmit16, Colorectal Transdisciplinary Study (CORECT), Colon Cancer Family 
Registry Study (CCFR), Genetics and Epidemiology of Colorectal Cancer 
Consortium (GECCO), Tracy A. O’Mara17, Amanda B. Spurdle17, Endometrial 
Cancer Association Consortium (ECAC), Puya Gharahkhani18, Johannes 
Schumacher19, Janusz Jankowski20,21, Ines Gocke22, Esophageal Cancer GWAS 
Consortium, Melissa L. Bondy23, Richard S. Houlston24, Robert B. Jenkins25, 
Beatrice Melin26, Glioma International Case Control Consortium (GICC), Corina 
Lesseur27,28, Andy R. Ness29,30, Brenda Diergaarde31,32, Andrew F. Olshan33,34, 
Head-Neck Cancer GWAS Consortium, Christopher I. Amos35, David C. 
Christiani8,36, Maria T. Landi6, James D. McKay28, International Lung Cancer 
Chen et al. Page 12













Consortium (ILCCO), Myriam Brossard37,38, Mark M. Iles39, Matthew H. Law18,40, 
Stuart MacGregor18, Melanoma GWAS Consortium, Jonathan Beesley17, Michelle 
R. Jones41, Jonathan Tyrer42, Stacey J. Winham43, Ovarian Cancer Association 
Consortium (OCAC), Alison P. Klein44,45, Gloria Petersen43, Donghui Li46, Brian M. 
Wolpin47, Pancreatic Cancer Case-Control Consortium (PANC4), Pancreatic Cancer 
Cohort Consortium (PanScan), Rosalind A. Eeles48,49, Christopher A. Haiman50, 
Zsofia Kote-Jarai48,49, Fredrick R. Schumacher51,52, PRACTICAL consortium, 
CRUK, BPC3, CAPS, PEGASUS, Paul Brennan29, Stephen J. Chanock6, Valerie 
Gaborieau29, Mark P. Purdue6, Renal Cancer GWAS Consortium, Paul Pharoah9, 
Rayjean J. Hung38, Laufey T. Amundadottir6, Peter Kraft7,8, Bogdan Pasaniuc2,53,54, 
Sara Lindström1,15,*
Affiliations
1Department of Epidemiology, University of Washington, Seattle, WA, USA
2Department of Pathology and Laboratory Medicine, David Geffen School of 
Medicine, University of California, Los Angeles, Los Angeles, CA, USA
3Department of Mathematics, Indian Institute of Technology Hyderabad, Kandi, 
Telangana, India
4Department of Environmental and Occupational Health Sciences, University of 
Washington, Seattle, WA, USA
5Medical Research Council Integrative Epidemiology Unit, Population Health 
Sciences, Bristol Medical School, University of Bristol, Bristol, UK
6Division of Cancer Epidemiology and Genetics, National Cancer Institute, National 
Institutes of Health, Bethesda, MD, USA
7Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, 
MA, USA
8Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, 
MA, USA
9Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary 
Care, University of Cambridge, Cambridge, UK
10Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, 
Cyprus
11Cyprus School of Molecular Medicine, Nicosia, Cyprus
12Department of Molecular Medicine, Faculty of Medicine, Université Laval and 
Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada
13Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
14Department of Epidemiology and Biostatistics, University of California at San 
Francisco, San Francisco, CA, USA
Chen et al. Page 13













15Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 
Seattle, WA, USA
16Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, 
Cleveland, OH, USA
17Department of Genetics and Computational Biology, QIMR Berghofer Medical 
Research Institute, Brisbane, Australia
18Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, 
Australia
19Center for Human Genetics, University Hospital of Marburg, Marburg, Germany
20College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, 
Abu Dhabi, UAE
21Comprehensive Clinical Trials Unit, University College London, London, UK
22Department of Visceral, Transplant, Thoracic, and Vascular Surgery, University 
Hospital of Leipzig, Leipzig, Germany
23Department of Epidemiology and Population Health, Stanford University, Palo Alto, 
CA, USA
24Division of Genetics and Epidemiology, The Institute of Cancer Research, London, 
UK
25Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive 
Cancer Center, Mayo Clinic, Rochester, MN, USA
26Department of Radiation Sciences, Umeå University, Umeå, Sweden
27Department of Environmental Medicine and Public Health, Icahn School of 
Medicine at Mount Sinai, New York, NY, USA
28International Agency for Research on Cancer, World Health Organization, Lyon, 
France
29National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, 
University Hospitals Bristol and Weston NHS Foundation Trust and the University of 
Bristol, Bristol, UK
30Bristol Dental School, University of Bristol, Bristol, UK
31Department of Human Genetics, Graduate School of Public Health, University of 
Pittsburgh, Pittsburgh, PA, USA
32UPMC Hillman Cancer Center, Pittsburgh, PA, USA
33Department of Epidemiology, Gillings School of Global Public Health, University of 
North Carolina at Chapel Hill, Chapel Hill, NC, USA
34UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
Chen et al. Page 14













35Institute for Clinical and Translational Research, Baylor College of Medicine, 
Houston, TX, USA
36Department of Environmental Health, Harvard T.H. Chan School of Public Health, 
Boston, MA, USA
37Genetic Epidemiology and Functional Genomics of Multifactorial Diseases Team, 
Institut National de la Santé et de la Recherche Médicale (INSERM), UMRS-1124, 
Université Paris Descartes, Paris, France
38Prosserman Centre for Population Health Research, Lunenfeld-Tanenbuaum 
Research Institute, Sinai Health System, Toronto, ON, Canada
39Leeds Institute for Data Analytics, University of Leeds, Leeds, UK
40School of Biomedical Sciences, Faculty of Health, and Institute of Health and 
Biomedical Innovation, Queensland University of Technology, Kelvin Grove, QLD, 
Australia
41Center for Bioinformatics and Functional Genomics, Department of Biomedical 
Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA
42Department of Oncology, University of Cambridge, Cambridge, UK
43Department of Health Science Research, Mayo Clinic, Rochester, MN, USA
44Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns 
Hopkins School of Medicine, Baltimore, MD, USA
45Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, 
Johns Hopkins School of Medicine, Baltimore, MD, USA
46Department of Gastrointestinal Medical Oncology, University of Texas MD 
Anderson Cancer Center, Houston, TX, USA
47Department of Medical Oncology, Dana Farber Harvard Cancer Center, Boston, 
MA, USA
48Oncogenetics Team, Division of Genetics and Epidemiology, The Institute of 
Cancer Research, London, UK
49Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK
50Department of Preventive Medicine, University of Southern California, Los 
Angeles, CA, USA
51Department of Epidemiology and Biostatistics, Case Western Reserve University, 
Cleveland, OH, USA
52Seidman Cancer Center, University Hospitals, Cleveland, OH, USA
53Department of Human Genetics, David Geffen School of Medicine, University of 
California, Los Angeles, Los Angeles, CA, USA
54Department of Computational Medicine, David Geffen School of Medicine, 
University of California, Los Angeles, Los Angeles, CA, USA
Chen et al. Page 15















B.M.W. has received research grants from Celgene and Eli Lilly and has consulting relationship with BioLineRx, 
Celgene, and Grail. R.A.E. has received speaker honoraria from the GU-ASCO meeting (January 2016), RMH FR 
meeting (November 2017, supported by Janssen), University of Chicago invited talk (May 2018), and ESMO 
(September 2019, supported by Bayer & Ipsen) and served as member of external expert committee at the Prostate 
Dx Advisory Panel (June 2020). All other authors declare no competing interests.
References
1. International Agency for Research on Cancer; and W.H.O (2020). GLOBOCAN 2020. https://
gco.iarc.fr/.
2. Siegel RL, Miller KD, Fuchs HE, and Jemal A (2021). Cancer Statistics, 2021. CA Cancer J. Clin 
71, 7–33. [PubMed: 33433946] 
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, 
and Hemminki K (2000). Environmental and heritable factors in the causation of cancer–analyses of 
cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med 343, 78–85. [PubMed: 
10891514] 
4. Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, Graff RE, Holst K, Möller 
S, Unger RH, et al.; Nordic Twin Study of Cancer (NorTwinCan) Collaboration (2016). Familial 
Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA 315, 68–76. [PubMed: 
26746459] 
5. Rashkin SR, Graff RE, Kachuri L, Thai KK, Alexeeff SE, Blatchins MA, Cavazos TB, Corley DA, 
Emami NC, Hoffman JD, et al. (2020). Pan-cancer study detects genetic risk variants and shared 
genetic basis in two large cohorts. Nat. Commun 11, 4423. [PubMed: 32887889] 
6. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, 
Vierkant RA, Larson MC, Kjaer SK, et al.; Wellcome Trust Case-Control Consortium; Australian 
Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer 
Association Consortium (OCAC); and Ovarian Cancer Association Consortium (OCAC) (2010). A 
genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. 
Nat. Genet 42, 874–879. [PubMed: 20852632] 
7. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon 
A, Schirmer C, McDonald GJ, et al. (2007). Multiple regions within 8q24 independently affect risk 
for prostate cancer. Nat. Genet 39, 638–644. [PubMed: 17401364] 
8. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, 
Olschwang S, Chiang T, Crowdy E, et al. (2007). Genome-wide association scan identifies a 
colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet 39, 989–994. [PubMed: 
17618283] 
9. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, 
Tymrakiewicz M, Jhavar S, Saunders E, et al.; UK Genetic Prostate Cancer Study Collaborators/
British Association of Urological Surgeons’ Section of Oncology; and UK Prostate testing for 
cancer and Treatment study (ProtecT Study) Collaborators (2009). Multiple loci on 8q24 associated 
with prostate cancer susceptibility. Nat. Genet 41, 1058–1060. [PubMed: 19767752] 
10. Couch FJ, Wang X, McWilliams RR, Bamlet WR, de Andrade M, and Petersen GM (2009). 
Association of breast cancer susceptibility variants with risk of pancreatic cancer. Cancer 
Epidemiol. Biomarkers Prev 18, 3044–3048. [PubMed: 19843670] 
11. Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, Leonard A, dos Santos Silva I, Ashworth 
A, Houlston R, and Peto J (2008). Association of genetic variants at 8q24 with breast cancer risk. 
Cancer Epidemiol. Biomarkers Prev 17, 702–705. [PubMed: 18349290] 
12. Ghoussaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, Pooley KA, Ramus 
SJ, Kjaer SK, Hogdall E, et al.; UK Genetic Prostate Cancer Study Collaborators/British 
Association of Urological Surgeons’ Section of Oncology; and UK ProtecT Study Collaborators 
(2008). Multiple loci with different cancer specificities within the 8q24 gene desert. J. Natl. 
Cancer Inst 100, 962–966. [PubMed: 18577746] 
Chen et al. Page 16













13. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, 
Bergthorsson JT, Agnarsson BA, Baker A, et al. (2007). Genome-wide association study identifies 
a second prostate cancer susceptibility variant at 8q24. Nat. Genet 39, 631–637. [PubMed: 
17401366] 
14. Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, Hayes RB, Kraft P, Wacholder 
S, Orr N, Berndt S, et al. (2009). Identification of a new prostate cancer susceptibility locus on 
chromosome 8q24. Nat. Genet 41, 1055–1057. [PubMed: 19767755] 
15. Zhang M, Wang Z, Obazee O, Jia J, Childs EJ, Hoskins J, Figlioli G, Mocci E, Collins I, Chung 
CC, et al. (2016). Three new pancreatic cancer susceptibility signals identified on chromosomes 
1q32.1, 5p15.33 and 8q24.21. Oncotarget 7, 66328–66343. [PubMed: 27579533] 
16. O’Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black 
A, Bolla MK, et al. (2018). Identification of nine new susceptibility loci for endometrial cancer. 
Nat. Commun 9, 3166. [PubMed: 30093612] 
17. Beesley J, Pickett HA, Johnatty SE, Dunning AM, Chen X, Li J, Michailidou K, Lu Y, Rider DN, 
Palmieri RT, et al.; kConFab Investigators; Australian Ovarian Cancer Study Group; ABCTB 
Investigators; and Ovarian Cancer Association Consortium (2011). Functional polymorphisms in 
the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS 
ONE 6, e24987. [PubMed: 21949822] 
18. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, 
Ahmed S, Ambrosone CB, et al.; Gene Environment Interaction and Breast Cancer in Germany 
(GENICA) Consortium (2011). A common variant at the TERT-CLPTM1L locus is associated 
with estrogen receptor-negative breast cancer. Nat. Genet. 43, 1210–1214. [PubMed: 22037553] 
19. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key 
T, Gronberg H, et al.; UK Genetic Prostate Cancer Study Collaborators/British Association of 
Urological Surgeons’ Section of Oncology; UK ProtecT Study Collaborators, The Australian 
Prostate Cancer BioResource; and PRACTICAL Consortium (2011). Seven prostate cancer 
susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet 43, 785–
791. [PubMed: 21743467] 
20. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan 
AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, et al. (2010). A genome-wide association 
study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 
5p15.33. Nat. Genet 42, 224–228. [PubMed: 20101243] 
21. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, Jakobsdottir M, 
Helgadottir H, Thorlacius S, Aben KK, et al. (2009). Sequence variants at the TERT-CLPTM1L 
locus associate with many cancer types. Nat. Genet 41, 221–227. [PubMed: 19151717] 
22. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, 
Boisselier B, Delattre JY, et al. (2009). Genome-wide association study identifies five 
susceptibility loci for glioma. Nat. Genet 41, 899–904. [PubMed: 19578367] 
23. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, Qureshi M, Dong Q, Gu X, 
Chen WV, et al. (2008). Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat. 
Genet 40, 1407–1409. [PubMed: 18978787] 
24. Yang X, Yang B, Li B, and Liu Y (2013). Association between TERT-CLPTM1L rs401681[C] 
allele and NMSC cancer risk: a meta-analysis including 45,184 subjects. Arch. Dermatol. Res 305, 
49–52. [PubMed: 22893025] 
25. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, 
Weinrich SL, and Shay JW (1994). Specific association of human telomerase activity with 
immortal cells and cancer. Science 266, 2011–2015. [PubMed: 7605428] 
26. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, and Ohtake Y (2001). A novel gene, CRR9, which 
was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. 
Biochem. Biophys. Res. Commun 280, 1148–1154. [PubMed: 11162647] 
27. Yang J, Lee SH, Goddard ME, and Visscher PM (2011). GCTA: a tool for genome-wide complex 
trait analysis. Am. J. Hum. Genet 88, 76–82. [PubMed: 21167468] 
28. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, 
Amundadottir LT, Figueroa JD, et al. (2015). Analysis of Heritability and Shared Heritability 
Chen et al. Page 17













Based on Genome-Wide Association Studies for Thirteen Cancer Types. J. Natl. Cancer Inst 107, 
djv279. [PubMed: 26464424] 
29. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, Duncan L, Perry JR, 
Patterson N, Robinson EB, et al.; ReproGen Consortium; Psychiatric Genomics Consortium; and 
Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3 
(2015). An atlas of genetic correlations across human diseases and traits. Nat. Genet 47, 1236–
1241. [PubMed: 26414676] 
30. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, 
Neale BM; and Schizophrenia Working Group of the Psychiatric Genomics Consortium (2015). 
LD Score regression distinguishes confounding from polygenicity in genome-wide association 
studies. Nat. Genet 47, 291–295. [PubMed: 25642630] 
31. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, 
Kuchenbaecker KB, Dennis J, et al. (2019). Shared heritability and functional enrichment across 
six solid cancers. Nat. Commun 10, 431. [PubMed: 30683880] 
32. Lindström S, Finucane H, Bulik-Sullivan B, Schumacher FR, Amos CI, Hung RJ, Rand K, Gruber 
SB, Conti D, Permuth JB, et al.; PanScan, GECCO and the GAME-ON Network: CORECT, 
DRIVE, ELLIPSE, FOCI, and TRICL-ILCCO (2017). Quantifying the Genetic Correlation 
between Multiple Cancer Types. Cancer Epidemiol. Biomarkers Prev 26, 1427–1435. [PubMed: 
28637796] 
33. Kraft P, Chen H, and Lindström S (2020). The Use Of Genetic Correlation And Mendelian 
Randomization Studies To Increase Our Understanding of Relationships Between Complex Traits. 
Curr. Epidemiol. Rep 7, 104–112. [PubMed: 33552841] 
34. Berisa T, and Pickrell JK (2016). Approximately independent linkage disequilibrium blocks in 
human populations. Bioinformatics 32, 283–285. [PubMed: 26395773] 
35. Bhattacharjee S, Rajaraman P, Jacobs KB, Wheeler WA, Melin BS, Hartge P, Yeager M, Chung 
CC, Chanock SJ, Chatterjee N; and GliomaScan Consortium (2012). A subset-based approach 
improves power and interpretation for the combined analysis of genetic association studies of 
heterogeneous traits. Am. J. Hum. Genet 90, 821–835. [PubMed: 22560090] 
36. Yang J, Ferreira T, Morris AP, Medland SE, Madden PA, Heath AC, Martin NG, Montgomer GW, 
Weedon MN, Loos RJ, et al.; Genetic Investigation of ANthropometric Traits (GIANT) 
Consortium; and DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium 
(2012). Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies 
additional variants influencing complex traits. Nat Genet 44, 369–375, S1–3. [PubMed: 22426310] 
37. Kichaev G, Yang WY, Lindstrom S, Hormozdiari F, Eskin E, Price AL, Kraft P, and Pasaniuc B 
(2014). Integrating functional data to prioritize causal variants in statistical fine-mapping studies. 
PLoS Genet 10, e1004722. [PubMed: 25357204] 
38. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, 
Rostamianfar A, et al.; NBCS Collaborators; ABCTB Investigators; and ConFab/AOCS 
Investigators (2017). Association analysis identifies 65 new breast cancer risk loci. Nature 551, 
92–94. [PubMed: 29059683] 
39. Huyghe JR, Bien SA, Harrison TA, Kang HM, Chen S, Schmit SL, Conti DV, Qu C, Jeon J, Edlund 
CK, et al. (2019). Discovery of common and rare genetic risk variants for colorectal cancer. Nat. 
Genet 51, 76–87. [PubMed: 30510241] 
40. Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, 
Gerges C, Anders M, et al.; Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON); 
Esophageal Adenocarcinoma GenEtics Consortium (EAGLE); and Wellcome Trust Case Control 
Consortium 2 (WTCCC2) (2016). Genome-wide association studies in oesophageal 
adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol 17, 1363–
1373. [PubMed: 27527254] 
41. Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il’yasova D, Kinnersley B, Ostrom QT, 
Labreche K, Chen Y, Armstrong G, et al.; GliomaScan Consortium (2017). Genome-wide 
association study of glioma subtypes identifies specific differences in genetic susceptibility to 
glioblastoma and non-glioblastoma tumors. Nat. Genet 49, 789–794. [PubMed: 28346443] 
42. Lesseur C, Diergaarde B, Olshan AF, Wünsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, 
Franceschi S, Lagiou P, et al. (2016). Genome-wide association analyses identify new 
Chen et al. Page 18













susceptibility loci for oral cavity and pharyngeal cancer. Nat. Genet 48, 1544–1550. [PubMed: 
27749845] 
43. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE, Johansson 
M, Xiao X, Li Y, et al.; SpiroMeta Consortium (2017). Large-scale association analysis identifies 
new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological 
subtypes. Nat. Genet 49, 1126–1132. [PubMed: 28604730] 
44. Law MH, Bishop DT, Lee JE, Brossard M, Martin NG, Moses EK, Song F, Barrett JH, Kumar R, 
Easton DF, et al.; GenoMEL Consortium; Essen-Heidelberg Investigators; SDH Study Group; Q-
MEGA and QTWIN Investigators; AMFS Investigators; and ATHENS Melanoma Study Group 
(2015). Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant 
melanoma. Nat. Genet 47, 987–995. [PubMed: 26237428] 
45. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, 
Riggan MJ, Chornokur G, et al.; AOCS study group; EMBRACE Study; GEMO Study 
Collaborators; HEBON Study; KConFab Investigators; and OPAL study group (2017). 
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat. 
Genet 49, 680–691. [PubMed: 28346442] 
46. Klein AP, Wolpin BM, Risch HA, Stolzenberg-Solomon RZ, Mocci E, Zhang M, Canzian F, Childs 
EJ, Hoskins JW, Jermusyk A, et al. (2018). Genome-wide meta-analysis identifies five new 
susceptibility loci for pancreatic cancer. Nat. Commun 9, 556. [PubMed: 29422604] 
47. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, 
Leongamornlert D, Anokian E, Cieza-Borrella C, et al.; Profile Study; Australian Prostate Cancer 
BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer 
Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate 
Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden 
(CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci 
(PEGASUS); and Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating 
Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium (2018). Association 
analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat. Genet 
50, 928–936. [PubMed: 29892016] 
48. Scelo G, Purdue MP, Brown KM, Johansson M, Wang Z, Eckel-Passow JE, Ye Y, Hofmann JN, 
Choi J, Foll M, et al. (2017). Genome-wide association study identifies multiple risk loci for renal 
cell carcinoma. Nat. Commun 8, 15724. [PubMed: 28598434] 
49. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, 
McVean GA, Abecasis GR; and 1000 Genomes Project Consortium (2015). A global reference for 
human genetic variation. Nature 526, 68–74. [PubMed: 26432245] 
50. Province MA, and Borecki IB (2013). A correlated meta-analysis strategy for data mining “OMIC” 
scans. Pac. Symp. Biocomput 2013, 236–246.
51. Southam L, Gilly A, Süveges D, Farmaki AE, Schwartzentruber J, Tachmazidou I, Matchan A, 
Rayner NW, Tsafantakis E, Karaleftheri M, et al. (2017). Whole genome sequencing and 
imputation in isolated populations identify genetic associations with medically-relevant complex 
traits. Nat. Commun 8, 15606. [PubMed: 28548082] 
52. Shi H, Mancuso N, Spendlove S, and Pasaniuc B (2017). Local Genetic Correlation Gives Insights 
into the Shared Genetic Architecture of Complex Traits. Am. J. Hum. Genet 101, 737–751. 
[PubMed: 29100087] 
53. Shi H, Kichaev G, and Pasaniuc B (2016). Contrasting the Genetic Architecture of 30 Complex 
Traits from Summary Association Data. Am. J. Hum. Genet 99, 139–153. [PubMed: 27346688] 
54. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, and Plagnol V 
(2014). Bayesian test for colocalisation between pairs of genetic association studies using 
summary statistics. PLoS Genet 10, e1004383. [PubMed: 24830394] 
55. Fang J, Jia J, Makowski M, Xu M, Wang Z, Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, et al.; 
PanScan Consortium; TRICL Consortium; and GenoMEL Consortium (2017). Functional 
characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by 
ZNF148. Nat. Commun 8, 15034. [PubMed: 28447668] 
56. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, 
Burdette L, et al. (2014). Imputation and subset-based association analysis across different cancer 
Chen et al. Page 19













types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 
5p15.33. Hum. Mol. Genet 23, 6616–6633. [PubMed: 25027329] 
57. Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shoresh N, Adrian J, Kawli T, Davis CA, Dobin A, 
Kaul R, et al.; ENCODE Project Consortium (2020). Expanded encyclopaedias of DNA elements 
in the human and mouse genomes. Nature 583, 699–710. [PubMed: 32728249] 
58. Machiela MJ, and Chanock SJ (2015). LDlink: a web-based application for exploring population-
specific haplotype structure and linking correlated alleles of possible functional variants. 
Bioinformatics 31, 3555–3557. [PubMed: 26139635] 
59. Cheng I, Kocarnik JM, Dumitrescu L, Lindor NM, Chang-Claude J, Avery CL, Caberto CP, Love 
SA, Slattery ML, Chan AT, et al. (2014). Pleiotropic effects of genetic risk variants for other 
cancers on colorectal cancer risk: PAGE, GECCO and CCFR consortia. Gut 63, 800–807. 
[PubMed: 23935004] 
60. Panagiotou OA, Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, Schumacher FR, Siddiq A, 
Papatheodorou SI, Stanford JL, et al.; PRACTICAL Consortium (2015). A genome-wide 
pleiotropy scan for prostate cancer risk. Eur. Urol. 67, 649–657. [PubMed: 25277271] 
61. Fehringer G, Kraft P, Pharoah PD, Eeles RA, Chatterjee N, Schumacher FR, Schildkraut JM, 
Lindström S, Brennan P, Bickeböller H, et al.; Ovarian Cancer Association Consortium (OCAC); 
PRACTICAL Consortium; Hereditary Breast and Ovarian Cancer Research Group Netherlands 
(HEBON); Colorectal Transdisciplinary (CORECT) Study; and African American Breast Cancer 
Consortium (AABC) and African Ancestry Prostate Cancer Consortium (AAPC) (2016). Cross-
Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals 
Novel Pleiotropic Associations. Cancer Res 76, 5103–5114. [PubMed: 27197191] 
62. Wu YH, Graff RE, Passarelli MN, Hoffman JD, Ziv E, Hoffmann TJ, and Witte JS (2018). 
Identification of Pleiotropic Cancer Susceptibility Variants from Genome-Wide Association 
Studies Reveals Functional Characteristics. Cancer Epidemiol. Biomarkers Prev 27, 75–85. 
[PubMed: 29150481] 
63. Cao X, Huang M, Zhu M, Fang R, Ma Z, Jiang T, Dai J, Ma H, Jin G, Shen H, et al. (2019). 
Mendelian randomization study of telomere length and lung cancer risk in East Asian population. 
Cancer Med 8, 7469–7476. [PubMed: 31605466] 
64. Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, Wade KH, Timpson NJ, Evans 
DM, Willeit P, et al.; Telomeres Mendelian Randomization Collaboration (2017). Association 
Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian 
Randomization Study. JAMA Oncol 3, 636–651. [PubMed: 28241208] 
65. Zhang C, Doherty JA, Burgess S, Hung RJ, Lindström S, Kraft P, Gong J, Amos CI, Sellers TA, 
Monteiro AN, et al.; GECCO and GAME-ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and 
TRICL (2015). Genetic determinants of telomere length and risk of common cancers: a Mendelian 
randomization study. Hum. Mol. Genet 24, 5356–5366. [PubMed: 26138067] 
66. James MA, Wen W, Wang Y, Byers LA, Heymach JV, Coombes KR, Girard L, Minna J, and You 
M (2012). Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 
5p15.33 locus. PLoS ONE 7, e36116. [PubMed: 22675468] 
67. Jia J, Bosley AD, Thompson A, Hoskins JW, Cheuk A, Collins I, Parikh H, Xiao Z, Ylaya K, 
Dzyadyk M, et al. (2014). CLPTM1L promotes growth and enhances aneuploidy in pancreatic 
cancer cells. Cancer Res 74, 2785–2795. [PubMed: 24648346] 
68. Ni Z, Tao K, Chen G, Chen Q, Tang J, Luo X, Yin P, Tang J, and Wang X (2012). CLPTM1L is 
overexpressed in lung cancer and associated with apoptosis. PLoS ONE 7, e52598. [PubMed: 
23300716] 
69. Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, Arslan AA, Beane-Freeman 
L, Bracci PM, Buring J, et al. (2014). Genome-wide association study identifies multiple 
susceptibility loci for pancreatic cancer. Nat. Genet 46, 994–1000. [PubMed: 25086665] 
70. Barrett JH, Taylor JC, Bright C, Harland M, Dunning AM, Akslen LA, Andresen PA, Avril MF, 
Azizi E, Bianchi Scarrà, G., et al.; GenoMEL Consortium (2015). Fine mapping of genetic 
susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. 
Int. J. Cancer 136, 1351–1360. [PubMed: 25077817] 
71. Kachuri L, Amos CI, McKay JD, Johansson M, Vineis P, Bueno-de-Mesquita HB, Boutron-Ruault 
MC, Johansson M, Quirós JR, Sieri S, et al. (2016). Fine mapping of chromosome 5p15.33 based 
Chen et al. Page 20













on a targeted deep sequencing and high density genotyping identifies novel lung cancer 
susceptibility loci. Carcinogenesis 37, 96–105. [PubMed: 26590902] 
72. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett 
HA, Shen HC, Smart CE, et al. (2013). Multiple independent variants at the TERT locus are 
associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45, 371–384, 
384e1–2. [PubMed: 23535731] 
73. Delgado DA, Zhang C, Chen LS, Gao J, Roy S, Shinkle J, Sabarinathan M, Argos M, Tong L, 
Ahmed A, et al. (2018). Genome-wide association study of telomere length among South Asians 
identifies a second RTEL1 association signal. J. Med. Genet 55, 64–71. [PubMed: 29151059] 
74. Do SK, Yoo SS, Choi YY, Choi JE, Jeon HS, Lee WK, Lee SY, Lee J, Cha SI, Kim CH, and Park 
JY (2015). Replication of the results of genome-wide and candidate gene association studies on 
telomere length in a Korean population. Korean J. Intern. Med. (Korean. Assoc. Intern. Med.) 30, 
719–726.
75. Li C, Stoma S, Lotta LA, Warner S, Albrecht E, Allione A, Arp PP, Broer L, Buxton JL, Da Silva 
Couto Alves A, et al. (2020). Genome-wide Association Analysis in Humans Links Nucleotide 
Metabolism to Leukocyte Telomere Length. Am. J. Hum. Genet 106, 389–404. [PubMed: 
32109421] 
76. Wang Z, Zhang Z, Guo Y, Shui H, Liu G, Jin T, and Wang H (2018). Shorter Telomere Length Is 
Associated with Increased Breast Cancer Risk in a Chinese Han Population: A Case-Control 
Analysis. J. Breast Cancer 21, 391–398. [PubMed: 30607160] 
77. Pellatt AJ, Wolff RK, Lundgreen A, Cawthon R, and Slattery ML (2012). Genetic and lifestyle 
influence on telomere length and subsequent risk of colon cancer in a case control study. Int. J. 
Mol. Epidemiol. Genet 3, 184–194. [PubMed: 23050049] 
78. Bai Y, Fu W, Guan X, Wu X, Li G, Wei W, Feng Y, Meng H, Li H, Li M, et al. (2020). Co-
exposure to multiple metals, TERT-CLPTM1L variants, and their joint influence on leukocyte 
telomere length. Environ. Int 140, 105762. [PubMed: 32380304] 
79. Turnbull C, Rapley EA, Seal S, Pernet D, Renwick A, Hughes D, Ricketts M, Linger R, 
Nsengimana J, Deloukas P, et al.; UK Testicular Cancer Collaboration (2010). Variants near 
DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat. Genet 42, 604–
607. [PubMed: 20543847] 
Chen et al. Page 21













Figure 1. Analytical pipeline for the study
Regions with significant pairwise local genetic correlation were first identified by ρHESS. 
For regions harboring disproportionally high shared heritability across cancers, joint test of 
ASSET two-sided meta-analysis and COJO conditional analysis was then repeatedly 
conducted to identify independent signals, until no variant reached genome-wide 
significance (p < 5 × 10−8) in two-sided ASSET meta-analysis. For each signal, GWAS 
summary statistics conditional on other signals of selected cancer were used in multi-trait 
fine-mapping to estimate the posterior probability of being causal.
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Figure 2. Pairwise local genetic correlation between selected cancer types at chromosome 
5p15.33 (982,252–2,132,442 bp)
Cancer pairs with statistically significant (p value < 0.05/1,703 = 2.94 × 10−5) local genetic 
correlation are annotated with an asterisk.
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Figure 3. Categorizing 14 cancer types into three tiers based on their p value distribution at 
5p15.33
Pattern A cancers (A) have one single peak by the TERT gene; pattern B cancers (B) have a 
broader signal at the CLPTM1L gene as well as a signal by the TERT gene; pattern C 
cancers (C) have no genome-wide significant association in this region. Genome-wide 
significant levels at p value = 5 × 10−8 are marked with red dashed line in (A)–(C). 
Distribution of Z scores at the 5p15.33 region from the GWAS results of ER-negative breast, 
glioma, and prostate cancer (D). Only variants with p < 0.05 for both cancers are included. 
While the associations for ER-negative breast cancer and glioma overlap, the SNP 
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associations with ER-negative breast cancer and prostate, as well as glioma and prostate, are 
in opposite directions.
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Figure 4. Distribution of two-sided subset-based meta-analysis p values across eight cancer types 
at the 5p15.33 region
Index variants of ten independent candidate signals, identified by the iterative COJO-ASSET 
analysis, are annotated and marked in red.
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Figure 5. Correlation matrix showing the pairwise linkage disequilibrium (LD) between 10 
candidate signals, identified using an iterative COJO-ASSET analysis
LD was calculated based on the European ancestry populations in 1000 Genomes (1000G) 
Project.
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Figure 6. Open chromatin in different cancer types
Genomic location of tissue-specific open chromatin narrow peaks, which were used as 
functional prior in the fine-mapping analysis.
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